Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    22

Stocks News & Analysis

stocks

Oracle earnings: Solid execution secures revenue target and mitigates investor concerns

We raise our fair value estimate for Oracle stock.
stocks

US dividend shares are getting a boost from the HALO trade. Can it last?

Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
stocks

Unconventional wisdom: A modern day bank run

Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,839.1026.300.30%
CAC 407,984.4457.37-0.71%
DAX 4023,589.6550.38-0.21%
Dow JONES (US)46,677.85739.42-1.56%
FTSE 10010,295.279.88-0.10%
HKSE25,482.50234.26-0.91%
NASDAQ22,311.98404.16-1.78%
Nikkei 22553,819.61633.35-1.16%
NZX 50 Index13,187.3411.95-0.09%
S&P 5006,672.62103.18-1.52%
S&P/ASX 2008,617.1029.200.34%
SSE Composite Index4,095.4533.65-0.82%

Market Movers